Article
Oncology
Taishi Hata, Kiyotaka Hagihara, Anna Tsutsui, Hiroki Akamatsu, Masayuki Ohue, Tatsushi Shingai, Mitsuyoshi Tei, Masakazu Ikenaga, Ho Min Kim, Hideki Osawa, Hiroyoshi Takemoto, Ken Konishi, Mamoru Uemura, Chu Matsuda, Tsunekazu Mizushima, Kohei Murata, Yuko Ohno, Yuichiro Doki, Hidetoshi Eguchi
Summary: The twice-daily regimen of UFT/LV showed noninferiority and no increase in adverse events compared to the conventional three-times-daily regimen. This provides more treatment options, especially for elderly or frail patients, highlighting the importance of personalized medicine.
Article
Biochemistry & Molecular Biology
Daisuke Kotani, Eiji Oki, Yoshiaki Nakamura, Hiroki Yukami, Saori Mishima, Hideaki Bando, Hiromichi Shirasu, Kentaro Yamazaki, Jun Watanabe, Masahito Kotaka, Keiji Hirata, Naoya Akazawa, Kozo Kataoka, Shruti Sharma, Vasily N. Aushev, Alexey Aleshin, Toshihiro Misumi, Hiroya Taniguchi, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Takayuki Yoshino
Summary: Circulating tumor DNA (ctDNA) analysis can help with risk stratification and treatment decisions for patients with resectable colorectal cancer (CRC). The study found that postsurgical ctDNA positivity was associated with higher recurrence risk and was the most significant prognostic factor for patients with stage II or III CRC. Furthermore, ctDNA positivity identified patients who derived benefit from adjuvant chemotherapy.
Article
Medicine, General & Internal
Siran M. Koroukian, Benjamin D. Booker, Long Vu, Fredrick R. Schumacher, Johnie Rose, Gregory S. Cooper, J. Eva Selfridge, Sarah C. Markt
Summary: This study aimed to identify factors associated with first-line targeted therapies among patients with metastatic colorectal cancer and investigate the association between targeted therapy and survival. The results showed that EGFR inhibitors were associated with improved survival in patients with RAS wildtype (RAS-WT) tumors, while no survival benefit was found with VEGF inhibitors in patients with RAS-WT or RAS mutant (RAS-Mut) tumors. Therefore, this study highlights the importance of using data from routine clinical care.
Review
Oncology
Bengt Glimelius, Sebastian Stintzing, John Marshall, Takayuki Yoshino, Aimery de Gramont
Summary: Despite recent advances in targeted therapies, chemotherapy with a combination of 5-FU and leucovorin remains the standard backbone of treatment for most mCRC patients, with focus on intracellular folate concentration as crucial in cytotoxic efficacy. Efforts to optimize and refine 5-FU treatments have included the use of 5-FU analogues and improving dosing schedules.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Hanla A. Park, Dominic Edelmann, Federico Canzian, Tabitha A. Harrison, Xinwei Hua, Qian Shi, Allison Silverman, Martin Schneider, Richard M. Goldberg, Steven R. Alberts, Michael Hoffmeister, Hermann Brenner, Andrew T. Chan, Ulrike Peters, Polly A. Newcomb, Jenny Chang-Claude
Summary: This study aimed to construct polygenic hazard scores (PHS) as predictive markers for oxaliplatin treatment outcome but could not be replicated in an independent cohort.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
(2022)
Article
Oncology
Boram Han, Bum Jun Kim, Hyeong Su Kim, Dae Ro Choi, Byoung Yong Shim, Kyung Hee Lee, Jin Won Kim, Jung Han Kim, Hunho Song, Jong Hyeok Kim, Choong Kee Park, Jung Woo Lee, Min-Jeong Kim, Dae Young Zang
Summary: The combination of gemcitabine, erlotinib, and S-1 showed acceptable toxicity profile and modest clinical benefits in patients with advanced pancreatic cancer. Major toxicities included neutropenia, fatigue, and infection.
Article
Medicine, General & Internal
Jeanne Tie, Joshua D. Cohen, Kamel Lahouel, Serigne N. Lo, Yuxuan Wang, Suzanne Kosmider, Rachel Wong, Jeremy Shapiro, Margaret Lee, Sam Harris, Adnan Khattak, Matthew Burge, Marion Harris, James Lynam, Louise Nott, Fiona Day, Theresa Hayes, Sue-Anne McLachlan, Belinda Lee, Janine Ptak, Natalie Silliman, Lisa Dobbyn, Maria Popoli, Ralph Hruban, Anne Marie Lennon, Nicholas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Cristian Tomasetti, Peter Gibbs
Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ning Li, Yuan Zhu, Lu-Ying Liu, Yan-Ru Feng, Wen-Ling Wang, Jun Wang, Hao Wang, Gao-Feng Li, Yuan Tang, Chen Hu, Wen-Yang Liu, Hua Ren, Shu-Lian Wang, Wei-Hu Wang, Yong-Wen Song, Yue-Ping Liu, Hui Fang, Yu Tang, Ning-Ning Lu, Bo Chen, Shu-Nan Qi, Xin-Fan Liu, Ye-Xiong Li, Jing Jin
Summary: The addition of oxaliplatin to postoperative capecitabine-based chemoradiotherapy did not improve treatment efficacy but increased the risk of severe acute toxic effects. Postoperative capecitabine with radiotherapy plays a fundamental role in the treatment of locally advanced rectal cancer.
Article
Medicine, General & Internal
Lingbin Meng, Ram Thapa, Maria G. Delgado, Maria F. Gomez, Rui Ji, Todd C. Knepper, Joleen M. Hubbard, Xuefeng Wang, Jennifer B. Permuth, Richard D. Kim, Damian A. Laber, Hao Xie
Summary: This study evaluated the association of age with treatment-related adverse events and survival in early-onsetmetastatic colorectal cancer (mCRC) patients and explored the potential underlying factors. The findings showed that patients with early-onset mCRC had worse survival outcomes and unique adverse event patterns, which could be partially attributed to distinct genomic profiles. Therefore, these findings may inform individualized management approaches in patients with early-onset mCRC.
Article
Multidisciplinary Sciences
Sang-A Kim, Hyejoo Park, Kui-Jin Kim, Ji-Won Kim, Ji Hea Sung, Milang Nam, Ju Hyun Lee, Eun Hee Jung, Koung Jin Suh, Ji Yun Lee, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee, Keun-Wook Lee
Summary: High baseline plasma AREG levels in CRC patients are associated with shorter PFS with cetuximab treatment, but not with PFS or overall survival after chemotherapy failure. AREG may decrease the anti-proliferative effect of cetuximab, but loses this effect after acquiring resistance. Plasma AREG could potentially serve as a biomarker for predicting clinical outcomes with cetuximab-based chemotherapy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Elena Elez, Maria Auxiliadora Gomez-Espana, Cristina Gravalos, Pilar Garcia-Alfonso, Maria Jose Ortiz-Morales, Ferran Losa, Inmaculada Ales Diaz, Begona Grana, Marta Toledano-Fonseca, Manuel Valladares-Ayerbes, Eduardo Polo, Mercedes Salgado, Eva Martinez de Castro, Maria Jose Safont, Antonieta Salud, Ana Ruiz-Casado, Josep Tabernero, Maria del Carmen Riesco, Antonio Rodriguez-Ariza, Enrique Aranda
Summary: This study supports the benefits of aflibercept plus FOLFIRI in treating mCRC patients, with VEGF-A levels below 1941pg/mL potentially serving as a biomarker to predict better outcomes. ACE levels did not show significant differences in treatment efficacy.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Ye Chen, Yu-Wen Zhou, Ke Cheng, Zhi-Ping Li, De-Yun Luo, Meng Qiu, Qiu Li, Xin Wang, Ya-Li Shen, Dan Cao, Yu Yang, Feng Bi, Ji-Yan Liu, Hong-Feng Gou
Summary: The study found that bevacizumab combined with S-1 and raltitrexed has promising antitumor activity and safety in refractory metastatic colorectal cancer.
Article
Oncology
Christophe Tournigand, Thierry Andre, Emmanuel Achille, Geirard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gerard Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, Aimery de Gramont
Summary: In metastatic colorectal cancer, the combination of fluorouracil (FU) with leucovorin (LV) plus irinotecan or oxaliplatin showed superior efficacy compared to FU + LV alone. This study investigated two treatment sequences and found that both achieved prolonged survival with similar efficacy, but had different toxicity profiles.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Eric Van Cutsem, Julien Taieb, Rona Yaeger, Takayuki Yoshino, Axel Grothey, Evaristo Maiello, Elena Elez, Jeroen Dekervel, Paul Ross, Ana Ruiz-Casado, Janet Graham, Takeshi Kato, Jose C. Ruffinelli, Thierry Andre, Edith Carriere Roussel, Isabelle Klauck, Melanie Groc, Jean-Claude Vedovato, Josep Tabernero
Summary: This study aimed to evaluate the efficacy, safety, and quality of life of the combination of encorafenib + binimetinib + cetuximab as first-line treatment for BRAF(V600E)-mutated mCRC. The results showed that this combination therapy was effective with a manageable safety profile.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jim P. Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, David D. Halbert, Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz-Josef Lenz, Anthony Helmstetter, W. Michael Korn, David B. Spetzler
Summary: The study identified a molecular signature, FOLFOXai, that can predict the efficacy of oxaliplatin-based chemotherapy combined with bevacizumab in patients with metastatic colorectal cancer, with predictive value for treatment adjustment and survival outcomes, and was validated in TRIBE2 samples.
CLINICAL CANCER RESEARCH
(2021)